BKR is co-operating with micro^xlabs and Fraunhofer Institut to obtain funding for the development of a suite of cost-effective, rapid, near-patient products for triage and monitoring of disease progression using rapid (less than 20-minute) IL-6 test for patients in critical care. Fraunhofer IZI will develop a novel, homogeneous assay which is easier to be automated on a cartridge. HomeCyte^TM (micro^xlab’s device) will perform unique, rapid, on-site developments using patient whole blood and will position the company to move forward with multiple/multiplex biomarkers (CRP, PCT, IL6) for risk stratification into mild, moderate and severely effected sepsis patients. Microfluidic engineering expertise will be the backbone of BKR’s contribution.

Through the BKR family, a new joint venture has been founded in the Netherlands. The purpose is to support development of affordable therapeutics. There are many indications of neglected diseases and we aim to promote mono- and combination therapies using our expertise in the manufacture of artesunate and pyroniradine.